Full metadata record
DC FieldValueLanguage
dc.creatorBendandi, M. (Maurizio)
dc.creatorRodriguez-Calvillo, M. (Mercedes)
dc.creatorInoges, S. (Susana)
dc.creatorLopez-Diaz-de-Cerio, A. (Ascensión)
dc.creatorPerez-Simon, J.A. (José Antonio)
dc.creatorRodriguez-Caballero, A. (Arancha)
dc.creatorGarcia-Montero, A. (A.)
dc.creatorAlmeida, J. (J.)
dc.creatorZabalegui, N. (Natalia)
dc.creatorGiraldo, P. (P.)
dc.creatorSan-Miguel, J.F. (Jesús F.)
dc.creatorOrfao, A. (Alberto)
dc.date.accessioned2011-07-04T11:32:58Z-
dc.date.available2011-07-04T11:32:58Z-
dc.date.issued2006-
dc.identifier.citationBendandi M, Rodriguez-Calvillo M, Inoges S, Lopez-Diaz de Cerio A, Perez-Simon JA, Rodriguez-Caballero A, et al. Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation. Leuk Lymphoma 2006 Jan;47(1):29-37.es_ES
dc.identifier.issn1029-2403-
dc.identifier.urihttps://hdl.handle.net/10171/18722-
dc.description.abstractBACKGROUND AND OBJECTIVE: To combine the use of idiotype-pulsed allogeneic dendritic cells (alloDC) and soluble protein Id conjugated with KLH (Id-KLH) in a vaccine strategy for multiple myeloma (MM). DESIGN AND METHODS: Four MM patients received the combined vaccine after having experienced disease relapse/progression following reduced intensity conditioning (RIC) allogeneic stem cell transplantation (alloSCT) and failure to rescue therapy with donor lymphocyte infusion or chemotherapy (CHT). RESULTS: Vaccination was well tolerated and induced an anti-KLH antibody response in all 4 patients as well as substantial cell proliferation. In contrast, no case showed similar effects against either tumor-specific Id or irrelevant isotype control immunoglobulins (Ig). In turn, vaccination was associated with modulation of biological responses linked to both inflammatory and T-cell activation, with secretion of effector Th1 cytokines. In particular, an important increase in the spontaneous ex vivo secretion of TNFalpha, IL-6 and IFNgamma as well as IL-2 and IL-10 was frequently observed prior to the fourth vaccination. Moreover, in vitro stimulation with Id-KLH and Id-KLH plus alloDC, but not with alloDC alone was associated with an enhanced number of TNF-alpha+ T-cells and an increased secretion of IFNgamma and IL-2 before the third and fourth vaccination. From a clinical standpoint, 2 patients had a transient response and 1 has stable disease after stopping vaccination, while 3 of them ultimately progressed. INTERPRETATION AND CONCLUSIONS: The results show for the first time that the use of Id-pulsed alloDC following RIC alloSCT is safe and feasible. However, crucial strategy improvements are warranted to possibly achieve clinical benefit.es_ES
dc.language.isoenges_ES
dc.publisherInforma Healthcarees_ES
dc.rightsinfo:eu-repo/semantics/closedAccess-
dc.subjectCancer Vaccines/immunologyes_ES
dc.subjectVaccines, Conjugate/therapeutic usees_ES
dc.titleCombined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation.es_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttp://informahealthcare.com/doi/abs/10.1080/10428190500272473es_ES

Files in This Item:
There are no files associated with this item.


Statistics and impact
0 citas en
0 citas en

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.